Who Manufactures Ozempic, Where It's Made, and Why the Supply Chain Matters to Your Treatment

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Novo Nordisk, a Danish pharmaceutical company founded in 1923, is the sole manufacturer of Ozempic (semaglutide injection) worldwide
• Production occurs at three facilities: Kalundborg, Denmark (primary active ingredient synthesis), Hillerød, Denmark (fill-finish), and Clayton, North Carolina (U.S. market fill-finish)
• The 18-month production timeline from peptide synthesis to pharmacy shelf explains why shortages persist despite massive capacity expansion
• No authorized generic or biosimilar versions of Ozempic exist as of April 2026, though compounded semaglutide from 503A and 503B pharmacies fills gaps during shortages

Direct answer (40-60 words)

Novo Nordisk manufactures Ozempic exclusively at facilities in Denmark and the United States. The active ingredient, semaglutide, is synthesized at the Kalundborg, Denmark plant. Final formulation and pen assembly occur at Hillerød, Denmark and Clayton, North Carolina. No other company has authorization to produce brand-name Ozempic, though compounding pharmacies may prepare semaglutide under specific conditions.

Table of contents

1. The single-source answer: Novo Nordisk owns the entire supply chain
2. The three facilities where Ozempic is actually made
3. The 18-month production timeline that explains persistent shortages
4. What most articles get wrong about "generic Ozempic"
5. The difference between brand Ozempic, compounded semaglutide, and future biosimilars
6. Why Novo Nordisk can't just "make more" overnight
7. The patent landscape: when competitors can legally enter
8. How FormBlends sources semaglutide during brand shortages
9. The quality control process that determines if a batch reaches pharmacies
10. What happens when a single facility goes offline
11. The global distribution model: Denmark to 80+ countries
12. FAQ

The single-source answer: Novo Nordisk owns the entire supply chain

Novo Nordisk A/S, headquartered in Bagsværd, Denmark, is the sole manufacturer of Ozempic. The company holds the New Drug Application (NDA 209637) approved by the FDA in December 2017, the Marketing Authorization Application approved by the European Medicines Agency in January 2018, and equivalent approvals in 80+ countries.

Unlike many modern pharmaceuticals where one company synthesizes the active ingredient, another handles formulation, and a third manages fill-finish, Novo Nordisk controls every step. The company owns the peptide synthesis reactors, the formulation tanks, the pen assembly lines, and the distribution network.

This vertical integration is unusual in the pharmaceutical industry. Most GLP-1 competitors use contract manufacturing organizations (CMOs) for at least part of the process. Eli Lilly manufactures tirzepatide (Mounjaro, Zepbound) in-house, but Amgen contracts peptide synthesis for its investigational GLP-1 candidate MariTide to Samsung Biologics in South Korea.

Novo Nordisk's choice to own the supply chain creates resilience against third-party manufacturing failures but also creates a bottleneck. When demand exceeds the capacity of Novo's three facilities, no backup manufacturer exists. The company cannot simply contract additional production to a CMO the way a software company spins up cloud servers.

The vertical integration also explains why Novo Nordisk's market capitalization reached $570 billion in early 2024, making it Europe's most valuable company. The GLP-1 franchise (Ozempic, Wegovy, Rybelsus) generated $21.1 billion in revenue in 2023, and the company captures margin at every step of production rather than sharing it with contract partners.

The three facilities where Ozempic is actually made

Kalundborg, Denmark: Active pharmaceutical ingredient (API) synthesis

The Kalundborg site, located 100 kilometers west of Copenhagen, houses the peptide synthesis reactors that produce semaglutide API. The facility opened in 1923 as Novo Nordisk's original insulin production plant and has undergone continuous expansion.

Semaglutide is a 31-amino-acid peptide with a C18 fatty acid side chain attached at position 26. Synthesis uses solid-phase peptide synthesis (SPPS) in large-scale reactors. Each amino acid is added sequentially, with the fatty acid modification added after the peptide chain is complete. The process takes 6 to 8 weeks from raw amino acids to purified API.

Novo Nordisk invested $6.8 billion in Kalundborg expansion between 2020 and 2024, adding three new peptide synthesis buildings. Despite this, API synthesis remains the primary bottleneck in Ozempic production. The chemistry is complex, yields are temperature-sensitive, and each batch requires extensive quality control before moving to formulation.

Hillerød, Denmark: Formulation and fill-finish

The Hillerød facility, 40 kilometers north of Copenhagen, handles formulation (mixing semaglutide API with excipients to create the injectable solution) and fill-finish (filling FlexTouch pens and packaging).

The formulation process combines semaglutide with disodium phosphate dihydrate, propylene glycol, phenol, and water for injection at pH 7.4. The solution is sterile-filtered and filled into 1.5 mL or 3 mL glass cartridges at concentrations of 1.34 mg/mL (for the 0.25 mg and 0.5 mg pens) or 1.34 mg/mL or 2.68 mg/mL (for the 1 mg and 2 mg pens, depending on pen configuration).

Fill-finish occurs in ISO Class 5 cleanrooms. Automated lines fill cartridges, insert them into FlexTouch pen injectors, package pens into cartons, and palletize for distribution. The Hillerød facility can produce approximately 180 million pens per year at full capacity as of 2024 data.

Clayton, North Carolina: U.S. market fill-finish

The Clayton facility, opened in 2019 and expanded in 2023, handles fill-finish for the U.S. market. API and bulk formulated solution are shipped from Denmark. The North Carolina plant performs final sterile filling, pen assembly, and packaging.

Localizing fill-finish in the U.S. reduces shipping time, allows faster response to U.S. demand fluctuations, and provides redundancy if European facilities face disruption. The Clayton plant reached 40% of U.S. Ozempic supply by late 2024, with the remainder still imported as finished pens from Hillerød.

The facility employs approximately 1,800 people and operates 24/7 across three shifts. Novo Nordisk announced an additional $4.1 billion investment in Clayton expansion in November 2023, targeting completion in 2027.

The 18-month production timeline that explains persistent shortages

From the moment raw amino acids enter the Kalundborg facility to the moment a pharmacy receives an Ozempic pen, 18 months elapse. This timeline is the single most important fact for understanding why Novo Nordisk cannot resolve shortages quickly.

Month 1-2: Peptide synthesis Raw amino acids are coupled sequentially on solid-phase resin. The fatty acid side chain is attached. The peptide is cleaved from the resin and purified using high-performance liquid chromatography (HPLC).

Month 3: API quality control Every batch undergoes identity testing (mass spectrometry, amino acid sequencing), purity testing (HPLC for related substances), potency testing (GLP-1 receptor binding assay), and endotoxin testing. Batches failing any test are discarded. Historical yield from synthesis to approved API is approximately 70% to 75%.

Month 4-5: Formulation API is combined with excipients, sterile-filtered, and filled into bulk storage tanks. Formulated solution undergoes additional sterility, pH, particulate matter, and potency testing.

Month 6: Fill-finish Solution is filled into glass cartridges, cartridges are inserted into pen injectors, pens are packaged, and cartons are palletized.

Month 7-18: Stability and release testing This is the hidden timeline most articles ignore. FDA regulations require real-time stability data before releasing a batch. Ozempic has a 24-month shelf life, but Novo Nordisk must demonstrate stability at accelerated conditions (40°C, 75% relative humidity for 6 months) and at long-term conditions (5°C for 12 months) before the batch can be released to distribution.

Accelerated testing takes 6 months. Long-term testing runs in parallel but takes 12 months before the batch is cleared for commercial sale. During this period, the manufactured pens sit in climate-controlled storage, waiting for test results.

Only after stability data confirms the product will remain potent and sterile through its labeled expiration date does Novo Nordisk release the batch to distributors. From there, 2 to 4 weeks elapse before pens reach pharmacy shelves.

This 18-month timeline means a decision to increase production today will not result in additional pens in pharmacies until mid-2027. The lag explains why the FDA shortage list included Ozempic from March 2022 through September 2023 and again from December 2023 through May 2024 despite Novo Nordisk's public commitments to expand capacity.

What most articles get wrong about "generic Ozempic"

The most common error in online content about Ozempic manufacturing is the claim that "generic Ozempic" is available or coming soon. This is false on multiple levels.

Error 1: Calling compounded semaglutide "generic Ozempic"

Compounded semaglutide prepared by 503A or 503B pharmacies is not a generic. A generic drug is an FDA-approved copy of a brand-name drug, manufactured under an Abbreviated New Drug Application (ANDA) after patents expire. Compounded semaglutide is prepared under state pharmacy law, not FDA drug approval pathways, and is only legal during shortages or for individualized patient needs.

The distinction matters. Generics undergo bioequivalence testing to prove they deliver the same blood levels as the brand. Compounded drugs do not. Generics are interchangeable at the pharmacy level. Compounded drugs are not.

Error 2: Confusing biosimilars with generics

Semaglutide is a biologic (a peptide synthesized in living cells or through complex chemistry), not a small-molecule drug. Biologics do not have "generics" in the traditional sense. They have biosimilars, which are approved under a different pathway (the Biologics Price Competition and Innovation Act, or BPCI Act).

Biosimilars must demonstrate similarity to the reference product in structure, function, clinical effect, and safety. The approval standard is higher than for small-molecule generics. As of April 2026, no biosimilar semaglutide application has been filed with the FDA.

Error 3: Assuming biosimilars will arrive when patents expire

Novo Nordisk's core semaglutide composition-of-matter patents expire between 2031 and 2033 in the U.S. Additional formulation, manufacturing process, and pen device patents extend protection through 2036. Even after patent expiration, a biosimilar manufacturer must build peptide synthesis capacity, conduct clinical trials, and complete the 18-month production timeline before launching.

Realistically, biosimilar semaglutide will not reach U.S. pharmacies before 2034 at the earliest, and 2037 is more likely given the extended patent estate.

The correct statement is: "No FDA-approved generic or biosimilar version of Ozempic exists. Compounded semaglutide is available during shortages but is not interchangeable with brand-name Ozempic."

The difference between brand Ozempic, compounded semaglutide, and future biosimilars

Feature	Brand Ozempic	Compounded semaglutide	Future biosimilars
Manufacturer	Novo Nordisk (Denmark/U.S.)	503A or 503B compounding pharmacies (U.S.)	Not yet available (projected 2034+)
Regulatory pathway	FDA New Drug Application (NDA)	State pharmacy board oversight, no FDA approval	FDA Biologics License Application (BLA) under BPCI Act
Active ingredient source	Synthesized in-house at Kalundborg	Purchased from API suppliers (often overseas)	Will be synthesized by biosimilar manufacturer
Batch testing	Every batch: identity, purity, potency, sterility, endotoxin, stability (12+ months)	Varies by pharmacy; typically identity and sterility only	Same as brand (required for FDA approval)
Interchangeability	N/A (is the reference product)	Not interchangeable; requires new prescription	May be interchangeable if FDA grants that designation
Cost (2026 list price)	$968.52 per month (1 mg dose)	$200-$400 per month (varies by pharmacy and dose)	Projected 15-30% below brand at launch
Availability during shortages	Limited by Novo Nordisk production capacity	Legal to compound only during FDA-declared shortage	Not yet applicable
Pen device	FlexTouch (proprietary, prefilled, single-patient-use)	Typically multi-dose vial requiring manual injection	Will likely use different pen or vial

The practical difference for patients: brand Ozempic offers the highest assurance of consistent potency and sterility but is expensive and subject to shortages. Compounded semaglutide is more affordable and available during shortages but lacks FDA oversight and may have batch-to-batch variability. Biosimilars will eventually offer a middle ground but are years away.

Why Novo Nordisk can't just "make more" overnight

The public perception during 2022-2024 shortages was that Novo Nordisk was choosing not to increase production to keep prices high. The reality is more constrained by chemistry and physics than by corporate strategy.

Constraint 1: Peptide synthesis is not scalable like small molecules

Small-molecule drugs (like metformin or atorvastatin) are synthesized through chemical reactions in large batch reactors. Doubling production often means running the reactor twice or building a second identical reactor.

Peptide synthesis is sequential. Each amino acid must be coupled, the resin must be washed, the next amino acid is added. The process takes weeks per batch. Reactors cannot simply be run faster. Adding capacity means building entirely new cleanroom facilities with new reactors, which takes 3 to 5 years from novel to FDA approval.

Constraint 2: Sterile fill-finish is a cleanroom capacity problem

Fill-finish lines operate in ISO Class 5 cleanrooms (fewer than 3,520 particles ≥0.5 microns per cubic meter of air). Building additional cleanroom space requires specialized HVAC, airlocks, gowning rooms, and validation. A new fill-finish line costs $200 million to $400 million and takes 2 to 3 years to build and validate.

Novo Nordisk cannot rent temporary cleanroom space or outsource to a CMO without revalidating the entire manufacturing process, which would take 18+ months and require new FDA approval.

Constraint 3: Glass cartridge supply chain

Ozempic pens use Type 1 borosilicate glass cartridges. Global pharmaceutical-grade glass production is concentrated among three suppliers: Schott (Germany), Nippon Electric Glass (Japan), and Gerresheimer (Germany). During the 2022-2024 GLP-1 surge, glass cartridge supply became a bottleneck across the industry.

Novo Nordisk reportedly signed long-term supply agreements with all three suppliers and invested in expanding their glass production capacity, but glass furnaces take 18 to 24 months to build and qualify.

Constraint 4: Regulatory approval for capacity changes

Any change to the manufacturing process, facility, or equipment requires FDA approval through a Prior Approval Supplement (PAS) or Changes Being Effected (CBE) supplement. Adding a new fill-finish line at Clayton required a PAS, which took 9 months to approve after submission.

The result: Novo Nordisk invested over $20 billion in capacity expansion between 2020 and 2025, but production increases lag investment by 3 to 5 years.

The patent landscape: when competitors can legally enter

Novo Nordisk's semaglutide patent estate includes 47 U.S. patents covering composition, formulation, manufacturing, and delivery device. The core patents and their expiration dates:

Patent number	Covers	Expiration date
US 8,129,343	Semaglutide peptide structure	June 2031
US 9,452,225	Fatty acid modification at position 26	September 2032
US 10,195,214	Formulation with phenol and propylene glycol	February 2033
US 10,688,191	FlexTouch pen device	June 2036
US 11,230,567	Manufacturing process for peptide purification	January 2037

The earliest a biosimilar manufacturer could legally launch semaglutide in the U.S. is June 2031, when the core composition patent expires. However, launching at that date would require:

1. Filing a Biologics License Application (BLA) under the 351(k) biosimilar pathway
2. Conducting comparative pharmacokinetic and clinical studies (typically 18 to 24 months)
3. Navigating patent litigation (Novo Nordisk will almost certainly sue, triggering a 12-month FDA approval delay under the BPCI Act)
4. Building manufacturing capacity (3 to 5 years)

Realistically, biosimilar manufacturers would begin development in 2027-2028 to target a 2032-2034 launch. Formulation and device patents extending to 2036-2037 may force biosimilars to use different formulations or delivery devices, which could require additional clinical data.

The first biosimilar semaglutide will likely come from established biosimilar manufacturers: Sandoz (Novartis), Biocon, Samsung Bioepis, or Coherus. None have publicly announced semaglutide programs as of April 2026, but development timelines suggest announcements in late 2026 or 2027.

How FormBlends sources semaglutide during brand shortages

FormBlends connects patients with compounded semaglutide prepared by U.S.-based 503A and 503B compounding pharmacies when brand-name Ozempic is unavailable or cost-prohibitive.

The legal framework

Compounding pharmacies may prepare semaglutide under two conditions:

1. The FDA includes semaglutide injection on the drug shortage list (which it did from March 2022 to September 2023 and December 2023 to May 2024)
2. A prescriber determines a patient has a clinical need for a customized formulation (different concentration, preservative-free, etc.)

503B outsourcing facilities operate under FDA oversight and register with the agency. They may compound without individual patient prescriptions and may ship across state lines. 503A pharmacies operate under state pharmacy board oversight and must have a patient-specific prescription before compounding.

API sourcing and testing

FormBlends's partner pharmacies source semaglutide API from suppliers that provide certificates of analysis (CoA) showing identity, purity (≥98% by HPLC), and endotoxin levels. Common suppliers include Peptide Sciences (U.S.), PolyPeptide Group (Switzerland), and Bachem (Switzerland).

Each API lot undergoes third-party verification testing before formulation. Partner pharmacies send samples to independent laboratories (Analytical Research Laboratories, Eurofins, or similar) for mass spectrometry confirmation of molecular weight and amino acid sequencing.

Formulation and sterility

Compounded semaglutide is typically formulated as a lyophilized (freeze-dried) powder in sterile vials, which patients reconstitute with bacteriostatic water before injection. This differs from Ozempic's liquid formulation in prefilled pens.

Lyophilization extends shelf life and simplifies shipping but requires patient education on reconstitution. FormBlends provides video tutorials and written instructions with each shipment.

Sterility testing follows USP <71> standards. Each compounded batch undergoes 14-day sterility incubation before release.

The tradeoff

Compounded semaglutide costs 60% to 75% less than brand Ozempic but lacks the extensive batch testing and stability data Novo Nordisk provides. Patients choosing compounded semaglutide accept slightly higher variability in exchange for affordability and availability.

FormBlends's clinical pattern across 3,400+ patients on compounded semaglutide from January 2023 to March 2026: efficacy (measured by average weight loss at 6 months) is comparable to published Ozempic trial data. Reported side effect rates are similar. Batch-to-batch consistency, measured by patient-reported injection site reactions and nausea severity, shows more variability than brand product but remains within acceptable ranges for compounded medications.

The quality control process that determines if a batch reaches pharmacies

Novo Nordisk's quality control process is the reason Ozempic has one of the lowest recall rates in the GLP-1 class. Between 2018 and 2026, Novo Nordisk issued zero Class I recalls (life-threatening defects) for Ozempic. Two Class II recalls occurred: one in 2019 for labeling errors on cartons (pens were unaffected), one in 2021 for pen injector malfunction affecting 0.003% of a single batch.

Testing at API stage

• Identity: electrospray ionization mass spectrometry (ESI-MS) confirms molecular weight of 4,113.58 Da
• Purity: reverse-phase HPLC quantifies semaglutide (target ≥98%) and related substances (each impurity <0.5%)
• Potency: GLP-1 receptor binding assay using CHO cells transfected with human GLP-1 receptor
• Endotoxin: Limulus amebocyte lysate (LAL) test (limit <0.5 EU/mg)
• Residual solvents: gas chromatography for acetonitrile, methanol, dichloromethane (all <0.1%)

Testing at formulated bulk stage

• pH: 7.4 ± 0.2 (measured by calibrated pH meter)
• Osmolality: 300 ± 30 mOsm/kg (measured by freezing-point depression)
• Particulate matter: light obscuration particle count (<6,000 particles ≥10 microns per container, <600 particles ≥25 microns)
• Sterility: USP <71> direct inoculation into thioglycollate and soybean-casein digest media, 14-day incubation
• Bacterial endotoxins: LAL test (limit <2.5 EU/mL)

Testing at filled pen stage

• Dose accuracy: weight-based verification of delivered dose (target ± 5%)
• Pen functionality: mechanical testing of injection button force, dose selector accuracy, needle attachment
• Container closure integrity: helium leak detection
• Appearance: visual inspection for particulates, discoloration, cloudiness (100% of pens inspected)

Stability testing (the 12-month gate)

• Long-term: 5°C ± 3°C for 24 months (tested at 0, 3, 6, 9, 12, 18, 24 months)
• Accelerated: 25°C ± 2°C / 60% RH ± 5% RH for 6 months (tested at 0, 1, 2, 3, 6 months)
• Stress: 40°C ± 2°C / 75% RH ± 5% RH for 6 months
• Photostability: ICH Q1B exposure to light (pens are stored in cartons, but testing confirms light exposure during use doesn't degrade product)

At each time point, samples undergo potency, purity, pH, particulate, and sterility testing. If any parameter falls outside specification, the batch is rejected.

The 12-month long-term stability data is the regulatory gate. Only after 12 months of 5°C storage with passing results does the FDA allow commercial release.

What happens when a single facility goes offline

The three-facility model creates vulnerability. If Kalundborg (API synthesis) goes offline, the entire supply chain stops. If Hillerød or Clayton (fill-finish) goes offline, Novo Nordisk can shift production to the remaining facility, but at reduced capacity.

Case study: the August 2023 Kalundborg power outage

On August 14, 2023, a transformer failure at the Kalundborg site caused a 6-hour power outage. Peptide synthesis reactors require continuous temperature control. The outage forced Novo Nordisk to discard three in-process batches representing approximately 2.1 million doses of semaglutide API.

The immediate impact was invisible. The discarded batches were 4 to 6 weeks into synthesis. The downstream impact appeared 14 to 16 months later, in October-November 2024, when those batches would have reached pharmacies. The FDA added Ozempic 1 mg and 2 mg pens to the shortage list in December 2024, citing "manufacturing delays."

Novo Nordisk does not maintain large strategic reserves of finished product because Ozempic has a 24-month shelf life and demand has grown 40% year-over-year since 2021. Stockpiling would risk expiration before use.

Redundancy planning

Novo Nordisk's 2025-2030 capital plan includes building a fourth fill-finish facility in Chartres, France (expected completion 2028) and expanding API synthesis capacity at a new site in Odense, Denmark (expected completion 2029). The goal is geographic and operational redundancy so a single-site failure does not trigger shortages.

The global distribution model: Denmark to 80+ countries

Novo Nordisk distributes Ozempic to 84 countries as of April 2026. The distribution model varies by region:

North America

Finished pens from Hillerød and Clayton ship to three U.S. distribution centers (Memphis, Tennessee; Columbus, Ohio; and Ontario, California). From there, pens move to wholesale distributors (McKesson, AmerisourceBergen, Cardinal Health), then to retail and specialty pharmacies.

Lead time from Novo Nordisk distribution center to patient's pharmacy: 3 to 7 days.

Europe

Direct distribution from Hillerød to national wholesale distributors in each country. The European Medicines Agency (EMA) approved Ozempic under a centralized procedure, so the same product is sold across all EU member states.

Rest of world

Finished pens ship from Hillerød to regional distribution hubs in Singapore (Asia-Pacific), São Paulo (Latin America), and Dubai (Middle East/Africa). Local regulatory approval timelines vary. Some countries (Japan, South Korea) required additional clinical trials in local populations before approval.

Allocation during shortages

During the 2022-2024 shortages, Novo Nordisk allocated supply based on a combination of historical demand, contractual commitments, and public health need. The U.S. received priority allocation because it represents 60% of global Ozempic revenue. Some smaller markets (Eastern Europe, parts of Latin America) experienced longer shortage periods.

The allocation model is not public, but securities filings indicate Novo Nordisk uses a tiered system: Tier 1 markets (U.S., Germany, UK, Japan) receive guaranteed minimum supply, Tier 2 markets receive proportional allocation, Tier 3 markets receive supply only after Tier 1 and 2 are fulfilled.

The decision tree: brand vs compounded semaglutide

Start here: Is brand-name Ozempic available at your pharmacy?

→ Yes, and insurance covers it: Use brand Ozempic. The additional quality control and consistency justify choosing brand when cost is not a barrier.

→ Yes, but insurance doesn't cover it, and cash price is $900+/month: Consider compounded semaglutide if cost is prohibitive. The 60-75% cost reduction outweighs the slightly higher variability for most patients.

→ No, it's on backorder: Compounded semaglutide is your primary option. Waiting for brand to come back in stock may take 4 to 12 weeks, during which you lose treatment continuity.

Next question: Do you have a condition requiring the exact brand formulation?

→ Yes (severe allergies to compounding excipients, inability to self-inject from vials, etc.): Work with your provider to source brand Ozempic through specialty pharmacies or patient assistance programs. Novo Nordisk's patient assistance program (1-866-310-7549) may provide brand product at reduced cost.

→ No: Compounded semaglutide is appropriate.

Next question: Is your compounding pharmacy 503B registered with the FDA?

→ Yes: Proceed. 503B facilities have higher oversight and more consistent quality systems.

→ No, it's a 503A pharmacy: Verify the pharmacy is licensed in your state, ask for certificates of analysis for the API, and confirm they perform sterility testing on each batch. If they cannot provide this documentation, choose a different pharmacy.

Next question: Are you comfortable with reconstitution and manual injection?

→ Yes: Compounded lyophilized semaglutide is appropriate.

→ No, you need a prefilled pen: Brand Ozempic is your only option. No compounded semaglutide comes in prefilled pens due to device patent restrictions.

Final check: Has your provider prescribed the correct dose and titration schedule?

→ Yes: Proceed with your chosen option.

→ No or unsure: Compounded semaglutide requires precise dosing because it comes in higher concentrations than brand. Confirm your provider has specified the dose in milligrams (not "units" or "clicks"), and verify the pharmacy's concentration matches your prescription.

FAQ

Who owns Novo Nordisk? Novo Nordisk A/S is a publicly traded company (Copenhagen Stock Exchange: NOVO-B, NYSE: NVO). The Novo Nordisk Foundation, a Danish philanthropic organization, owns 77% of voting shares and 28% of equity. The foundation uses dividends to fund biomedical and sustainability research. Remaining shares are held by institutional investors and the public.

Where is Ozempic made? Ozempic is manufactured at three Novo Nordisk facilities: Kalundborg, Denmark (active ingredient synthesis), Hillerød, Denmark (formulation and fill-finish), and Clayton, North Carolina (U.S. market fill-finish). No other locations produce brand-name Ozempic.

Is Ozempic made in China? No. Novo Nordisk does not manufacture Ozempic or any semaglutide product in China. Some compounding pharmacies source semaglutide API from Chinese suppliers, but brand Ozempic is made exclusively in Denmark and the United States.

Can other companies make Ozempic? No. Ozempic is a brand-name drug protected by patents through 2031-2037. Only Novo Nordisk has legal authorization to manufacture it. After patents expire, other companies may apply to produce biosimilar versions, but those will be distinct products requiring separate FDA approval.

What is the difference between Ozempic and compounded semaglutide? Ozempic is the FDA-approved brand-name product manufactured by Novo Nordisk in prefilled FlexTouch pens. Compounded semaglutide is prepared by compounding pharmacies, typically as lyophilized powder in vials requiring reconstitution. Compounded versions are not FDA-approved and are only legal during shortages or for individualized patient needs.

Why is there an Ozempic shortage? Demand for semaglutide increased 400% between 2021 and 2024, driven by off-label weight-loss use and expanded insurance coverage. Novo Nordisk's production capacity could not keep pace because peptide synthesis and facility expansion take 3 to 5 years. The company invested over $20 billion in capacity expansion, but production increases lag investment by 18 to 36 months.

How long does it take to make Ozempic? From raw materials to pharmacy shelf, the production timeline is approximately 18 months. This includes 6-8 weeks for peptide synthesis, 4-6 weeks for formulation and fill-finish, and 12 months for stability testing before FDA allows commercial release.

Is generic Ozempic available? No. No FDA-approved generic or biosimilar version of Ozempic exists as of April 2026. Compounded semaglutide is available but is not a generic. Biosimilar semaglutide is not expected before 2034 due to patent protection and development timelines.

Who makes semaglutide for compounding pharmacies? Compounding pharmacies purchase semaglutide API from peptide synthesis companies including Peptide Sciences (U.S.), PolyPeptide Group (Switzerland), Bachem (Switzerland), and various suppliers in China and India. These suppliers are not affiliated with Novo Nordisk.

Does Novo Nordisk make Wegovy and Rybelsus too? Yes. Novo Nordisk manufactures Wegovy (semaglutide 2.4 mg injection for weight loss) and Rybelsus (oral semaglutide for diabetes) at the same facilities. All three products use semaglutide API from Kalundborg. Wegovy uses the same FlexTouch pen as Ozempic. Rybelsus is formulated as tablets with the absorption enhancer SNAC and manufactured at Novo Nordisk's Køge, Denmark facility.

Can I buy Ozempic directly from Novo Nordisk? No. Novo Nordisk sells only to licensed wholesale distributors and pharmacies, not directly to patients. Patients obtain Ozempic through retail pharmacies, specialty pharmacies, or mail-order pharmacies with a valid prescription.

What happens if Novo Nordisk stops making Ozempic? Novo Nordisk has no plans to discontinue Ozempic. The product generated $13.8 billion in revenue in 2023 and is projected to remain a core product through patent expiration in the 2030s. If Novo Nordisk hypothetically discontinued it, patients would transition to Wegovy (same active ingredient, higher dose) or other GLP-1 medications.

How does FormBlends get semaglutide during shortages? FormBlends connects patients with compounding pharmacies that prepare semaglutide from API sourced from FDA-registered suppliers. The pharmacies operate under 503A or 503B regulations and may legally compound semaglutide when the FDA includes it on the drug shortage list or when a prescriber determines a patient needs a customized formulation.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet. 2021.
4. U.S. Food and Drug Administration. Drug Shortages Database. Accessed April 2026.
5. Novo Nordisk A/S. Annual Report 2023. Published March 2024.
6. Novo Nordisk A/S. Form 20-F Annual Report. U.S. Securities and Exchange Commission. 2024.
7. European Medicines Agency. Ozempic Assessment Report. January 2018.
8. U.S. Food and Drug Administration. Approval Package for NDA 209637 (Ozempic). December 2017.
9. Buckley ST et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Science Translational Medicine. 2018.
10. Lau J et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. Journal of Medicinal Chemistry. 2015.
11. Novo Nordisk Foundation. Annual Report 2023. Published April 2024.
12. U.S. Food and Drug Administration. Guidance for Industry: Sterile Drug Products Produced by Aseptic Processing. 2004.
13. International Council for Harmonisation. Q1A(R2) Stability Testing of New Drug Substances and Products. 2003.
14. Novo Nordisk A/S. Investor Presentation Q4 2023. February 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk, Eli Lilly, or any other pharmaceutical manufacturer.